Compugen to Screen Peptides for Pfizer | GenomeWeb

NEW YORK (GenomeWeb News) – Compugen said today that it will screen peptide candidates for three Pfizer drug targets.

Under the collaboration, Compugen will use its predictive models, algorithms, and computational biology methods to discover and synthesize molecules for the drug maker. Pfizer will pay Compugen for the research, and it will have the right to options for worldwide and exclusive milestones and licenses to develop and commercialize the selected candidates, Compugen said.

Compugen said it expects the studies to take a few months.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.